[Articles] Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis

May, 05, 2024 | Select Oncology Journal Articles

Fewer than a third of indications approved with immature survival data showed a statistically significant overall survival benefit after approval. Notable inconsistencies in timing and availability of information after approval across different sources emphasise the need for better reporting standards.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy